SAB Biotherapeutics (SABS) Asset Utilization Ratio (2021 - 2024)

SAB Biotherapeutics (SABS) has 4 years of Asset Utilization Ratio data on file, last reported at 0.03 in Q4 2024.

• Quarterly Asset Utilization Ratio fell 32.33% year-over-year to 0.03 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.03 (down 32.33% YoY) and the FY2024 annual result came in at 0.02, down 37.84% from the prior year.
• Asset Utilization Ratio grew to 0.03 in Q4 2024, from 0.03 in the prior quarter.
• In the past five years, Asset Utilization Ratio ranged from a high of 0.75 in Q1 2022 to a low of 0.03 in Q3 2024.
• A 4-year average of 0.29 and a median of 0.16 in 2023 frame the typical range for Asset Utilization Ratio.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio slipped 24.79% — and 2023, when it plunged 91.37%.
• Tracing SABS's Asset Utilization Ratio over 4 years: stood at 0.61 in 2021, then dropped by 24.79% to 0.46 in 2022, then sank by 91.37% to 0.04 in 2023, then sank by 32.33% to 0.03 in 2024.
• The last three Asset Utilization Ratio figures came in at 0.03 (Q4 2024), 0.03 (Q3 2024), and 0.04 (Q2 2024), per Business Quant data.